Melanotan II (MT-2) is a synthetic cyclic lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that has been extensively investigated in preclinical melanocortin receptor research. Developed at the University of Arizona by Dr. Victor Hruby and colleagues in the early 1990s, MT-2 was designed as a superpotent, non-selective melanocortin receptor agonist for use as a pharmacological research tool. It has since become one of the most widely studied melanocortin analogs in the preclinical literature.
Alpha-MSH Analog Design
Alpha-MSH is a 13-amino-acid linear peptide derived from the precursor protein proopiomelanocortin (POMC). It is the endogenous agonist for melanocortin receptors, with particular relevance to MC1R-mediated melanogenesis. However, native alpha-MSH has limited utility as a research tool due to its rapid enzymatic degradation in biological systems, resulting in a very short half-life measured in minutes.
MT-2 was engineered to overcome this limitation through several structural modifications. The peptide was shortened to a seven-amino-acid core sequence, cyclized through a lactam bridge between the side chains of aspartic acid and lysine residues, and incorporates a D-phenylalanine substitution at position 7. These modifications collectively increase resistance to enzymatic degradation, enhance receptor binding affinity, and improve metabolic stability. The resulting cyclic peptide has a molecular weight of approximately 1024.2 Daltons.
Melanocortin Receptor Binding Profile
In-vitro receptor binding studies have characterized MT-2 as a potent, non-selective agonist with activity across multiple melanocortin receptor subtypes. Competitive binding assays using radiolabeled NDP-alpha-MSH have demonstrated that MT-2 displaces the radioligand from MC1R, MC3R, MC4R, and MC5R with nanomolar to sub-nanomolar affinity. Functional assays measuring cyclic AMP accumulation have confirmed full agonist activity at these receptor subtypes.
The MC1R binding activity of MT-2 has been of particular research interest. MC1R is expressed primarily on melanocytes and is the key receptor mediating the melanogenesis signaling cascade. Upon MC1R activation, the Gs-cAMP-PKA pathway stimulates the expression of microphthalmia-associated transcription factor (MITF), which in turn drives the transcription of tyrosinase and other melanogenic enzymes. In-vitro melanocyte culture studies have demonstrated that MT-2 treatment increases melanin production in a dose-dependent manner consistent with MC1R agonism.
Preclinical Melanocortin Research Applications
MT-2 has served as a valuable pharmacological tool across multiple areas of melanocortin system research. In melanocyte biology, it is used to study the signaling pathways downstream of MC1R activation, including the cAMP-MITF-tyrosinase axis. Researchers have used MT-2 in combination with selective MC1R antagonists to dissect the contribution of MC1R versus other melanocortin receptors to observed cellular responses.
In neuroscience research, the MC3R and MC4R activity of MT-2 has been investigated in the context of central melanocortin system function. Animal studies using c-Fos immunohistochemistry have mapped the pattern of neuronal activation following MT-2 administration, revealing activation in hypothalamic and limbic brain regions consistent with known MC3R and MC4R expression patterns. These studies have contributed to the understanding of central melanocortin circuitry and its role in integrating neuroendocrine signals.
Receptor Selectivity Research
Because MT-2 is a non-selective melanocortin agonist, it has been used extensively in comparative pharmacology studies alongside receptor-selective compounds. By comparing the effects of MT-2 to those of MC4R-selective agonists, MC3R-selective agonists, and receptor subtype-specific antagonists, researchers can delineate which effects are mediated by specific receptor subtypes. This pharmacological dissection approach has been fundamental to understanding the functional roles of individual melanocortin receptors in preclinical models.
The development of more selective melanocortin agonists and antagonists has been informed by structure-activity relationship studies using MT-2 as a starting template. Systematic modification of the MT-2 core sequence has yielded analogs with varying degrees of receptor subtype selectivity, providing researchers with an expanding toolkit for melanocortin receptor pharmacology.
Stability and Handling
The cyclic lactam structure of MT-2 confers substantially greater metabolic stability compared to linear alpha-MSH. In-vitro degradation studies have demonstrated resistance to common serum proteases and peptidases. MT-2 is supplied as a lyophilized powder and should be stored at negative twenty degrees Celsius for long-term preservation. Reconstitution is performed with bacteriostatic water, and the solution should be stored at two to eight degrees Celsius and used within three to four weeks. The reconstituted solution should be clear and colorless; any turbidity may indicate aggregation or degradation.
Research Use Disclaimer
MT-2 is sold exclusively for in-vitro and preclinical research purposes. It is not approved for human consumption, veterinary use, or therapeutic application. All pharmacological data described in this article is derived from cell culture systems and animal models. Researchers must ensure compliance with all applicable institutional and regulatory requirements when using MT-2 in experimental protocols. No claims of clinical efficacy or safety are made.